

Drugs and Devices Division

Drug Submission Status

Report for November 2018

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Marcan Pharmaceuticals Inc.	Mar-Methimazole	Tapazole	thiamazole	10mg	tablet	02480115
Fresenius Kabi Canada Ltd.	Zoledronic Acid for Injection	Zometa Concentrate	zoledronic acid monohydrate	4 mg/5 mL	IV solution	02434458
Mylan Pharmaceuticals ULC	Mylan-Vardenafil	Levitra	vardeafil HCl trihydrate	5 mg	FC tablet	02464209
Mylan Pharmaceuticals ULC	Mylan-Vardenafil	Levitra	vardeafil HCl trihydrate	10mg	FC tablet	02464225
Mylan Pharmaceuticals ULC	Mylan-Vardenafil	Levitra	vardeafil HCl trihydrate	20 mg	FC tablet	02464233

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp-Montelukast	Singulair	montelukast sodium	5mg	chewable tablet	02442361
Jamp Pharma Corporation	Jamp-Vardenafil IR	Levitra	vardenafil HCl	5mg	FC tablet	02475677
Jamp Pharma Corporation	Jamp-Vardenafil IR	Levitra	vardenafil HCl	10mg	FC tablet	02475685
Jamp Pharma Corporation	Jamp-Vardenafil IR	Levitra	vardenafil HCl	20mg	FC tablet	02475693